Table 5.
Comparison between responders and non-responders in both hepatitis C groups
| Variable | Responders n =43 | Non Responders n =30 | P |
| Gender | |||
| Male | 38 (88.4) | 26 (86.7) | NS1 |
| Female | 5 (11.6) | 4 (13.3) | |
| Body mass (kg, Mean ± SD) | |||
| Before treatment | 80.1 ± 10.6 | 75.1 ± 10.9 | NS1 |
| After treatment | 76.9 ± 10.6 | 72.9 ± 11.5 | NS1 |
| ALT | |||
| Pre treatment | 141.1 ± 88.9 | 101.2 ± 41.0 | NS1 |
| 12 wk | 56.2 ± 55.0 | 67.1 ± 44.0 | NS1 |
| 48 wk | 38.1 ± 22.7 | 65.0 ± 30.6 | NS1 |
| NS1 | |||
| PCR (No. of viruses in BL; mean ± SD) | |||
| Pre treatment | 416 328 ± 341 106 | 337 321 ± 482 826 | 0.036 |
| Liver fibrosis | |||
| Grade 1 | 17 (39.5) | 3 (10.3) | 0.009 |
| Grade 2 | 17 (39.5) | 11 (37.9) | |
| Grade 3 | 8 (18.6) | 8 (27.6) | |
| Grade 4 | 1 (2.4) | 7 (24.1) | |
| HCV vs HCV and Bilharziasis | |||
| Co-infected | 37 (84.1) | 24 (82.8) | NS1 |
| Non Bilharzial | 7 (15.9) | 5 (17.2) | |
| Drug used | |||
| Pegasus | 29 (67.4) | 9 (30.0) | 0.002 |
| Non-pegylated IFN | 14 (32.6) | 21 (70.0) | |
1
Not significant.